For weight management in people without diabetes, NICE recommends considering specific GLP-1 agonists (semaglutide 2.4mg or liraglutide 3mg) only in specialist weight management services, for individuals with a BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) who have weight-related comorbidities
doi: 10.2147/DDDT.S365416
No successful phase-three Pinealon programme was identified
When retatrutide activates GIP receptors alongside GLP-1 and glucagon receptors, the combined effect on intestinal secretions, motility, and absorption patterns creates a complex new digestive environment
Local, intra-VTA GLP-1R activation appears to align with the latter reports and does not result in any changes in non-goal oriented motor activity (Dickson et al., 2012)